ORIC Pharmaceuticals, Inc. develops clinical-stage oncology therapies designed to counter mechanisms of therapeutic resistance in cancer. News about ORIC commonly covers rinzimetostat (ORIC-944), a selective allosteric PRC2/EED inhibitor studied in prostate cancer and metastatic castration-resistant prostate cancer, and enozertinib (ORIC-114), a brain-penetrant selective inhibitor targeting EGFR exon 20 insertion mutations and EGFR atypical mutations.
Recurring updates include clinical and preclinical data presentations, development-dose decisions, oncology conference presentations, quarterly financial results, cash runway disclosures, at-the-market equity financing, and Nasdaq Rule 5635(c)(4) inducement equity grants.
ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC) announced on February 1, 2023, the grant of 35,596 non-qualified stock options and 5,948 restricted stock units to three new non-executive employees. These inducement grants are part of the 2022 Inducement Equity Incentive Plan and are contingent on continued employment through each vesting date. The stock options' exercise price aligns with the closing price on the Grant Date. Vesting occurs over a span of time, with 25% vesting after one year and the remainder vesting monthly. The grants were approved by the Compensation Committee in compliance with Nasdaq regulations.
ORIC Pharmaceuticals, a clinical stage oncology company, announced its management's participation in two key investor conferences in February 2023. The Guggenheim Healthcare Talks Oncology Day will feature a fireside chat on February 8 at 3:20 p.m. ET, followed by the Citi 2023 Virtual Oncology Leadership Summit on February 22 at 11:00 a.m. ET. Investors can access live webcasts through the company's website. ORIC is focused on developing treatments targeting mechanisms of resistance in cancer, with product candidates including ORIC-533, ORIC-114, and ORIC-944.
ORIC Pharmaceuticals (Nasdaq: ORIC) announced key updates and milestones for its clinical pipeline on January 9, 2023. The company expects initial Phase 1b data for three ongoing trials—ORIC-533, ORIC-114, and ORIC-944—in the second half of 2023. Additionally, a new candidate was selected for its PLK4 synthetic lethal program targeting breast cancer. With $228 million in cash and investments, ORIC's funding is projected to last through the first half of 2025, supported by a recent $25 million investment from Pfizer.
ORIC Pharmaceuticals, a clinical stage oncology company, announced that CEO Jacob M. Chacko will present a company overview at the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023, at 11:15 a.m. PT. The presentation will focus on ORIC's innovative treatments that address therapeutic resistance in cancer, including lead candidates ORIC-533, ORIC-114, and ORIC-944. A live webcast will be available on the company’s investor website, with a replay accessible for 90 days post-event.
ORIC Pharmaceuticals has announced a clinical collaboration with Pfizer for a Phase 2 study of ORIC-533, aimed at treating multiple myeloma. As part of the agreement, ORIC will receive a $25 million equity investment from Pfizer, extending its cash runway into the first half of 2025. ORIC-533, an oral CD73 inhibitor, will be evaluated in combination with elranatamab, a bispecific antibody targeting B-cell maturation antigen. Jeff Settleman, Pfizer's Chief Scientific Officer, will join ORIC’s Scientific Advisory Board to support the development process.
ORIC Pharmaceuticals (Nasdaq: ORIC) has presented promising preclinical data for its CD73 inhibitor, ORIC-533, showing potential as a best-in-class treatment for multiple myeloma. The data exhibit ORIC-533's ability to significantly reduce adenosine generation, overcoming immune suppression and leading to the effective lysis of multiple myeloma cells in ex vivo models. The company anticipates sharing initial clinical data from the ongoing Phase 1b trial in the first half of 2023, highlighting the potential of ORIC-533 to impact treatment outcomes for patients with this challenging cancer.
ORIC Pharmaceuticals, a clinical-stage oncology firm, will participate in a fireside chat at the Jefferies London Healthcare Conference on November 16, 2022, at 5:35 p.m. GMT. The discussion will be available via a live webcast on the company’s investor website, with a replay accessible for 90 days post-event.
ORIC is focused on developing therapies to combat cancer resistance, with candidates including ORIC-533 for multiple myeloma, ORIC-114 targeting specific cancer mutations, and ORIC-944 for prostate cancer. For more information, visit www.oricpharma.com.
ORIC Pharmaceuticals reported financial results for Q3 2022, highlighting significant developments in its oncology pipeline. The company has cash and investments of $218.0 million, expected to fund operations into 2H 2024. Key clinical advancements include FDA clearance for ORIC-114's US IND and ongoing Phase 1b trials for ORIC-533, ORIC-114, and ORIC-944. R&D expenses for Q3 2022 increased to $14.7 million, primarily driven by product advancement efforts. Initial Phase 1b data for these studies is anticipated in 1H 2023.
ORIC Pharmaceuticals announced a preclinical poster presentation of ORIC-533 at the 64th ASH Annual Meeting on December 10-13, 2022. The presentation, titled "CD73 Inhibition Reverses Immunosuppression and Has Potential As an Immunomodulatory Therapy in Patients with Multiple Myeloma," showcases ORIC-533's best-in-class profile as a CD73 inhibitor. Key findings include ORIC-533's ability to overcome immune suppression and significantly lyse multiple myeloma cells in vitro. A Phase 1b trial is ongoing, with initial data expected in H1 2023.
On October 3, 2022, ORIC Pharmaceuticals granted 116,560 non-qualified stock options and 19,435 restricted stock units to five new non-executive employees, effective from September 2022. These inducement grants, part of the 2022 Inducement Equity Incentive Plan, require continued employment for vesting. Stock options will vest 25% after one year, with monthly vesting thereafter, while one-third of restricted stock units will vest annually over three years. This was approved under Nasdaq Rule 5635(c)(4) as a material inducement for employment.